Front-line treatment of brain parenchyma relapse
| Treatment . | Patients, no. (%) . |
|---|---|
| Total | 113 |
| Chemotherapy only | 52 (46) |
| Methotrexate-based | 49 (43) |
| Other chemotherapy* | 3 (3) |
| Chemotherapy and WBRT | 26 (23) |
| Methotrexate-based | 22 (19) |
| Other chemotherapy† | 4 (4) |
| WBRT only | 34 (30) |
| Brain surgery only‡ | 1 (1) |
| Treatment . | Patients, no. (%) . |
|---|---|
| Total | 113 |
| Chemotherapy only | 52 (46) |
| Methotrexate-based | 49 (43) |
| Other chemotherapy* | 3 (3) |
| Chemotherapy and WBRT | 26 (23) |
| Methotrexate-based | 22 (19) |
| Other chemotherapy† | 4 (4) |
| WBRT only | 34 (30) |
| Brain surgery only‡ | 1 (1) |
WBRT indicates whole brain radiotherapy.
Other chemotherapies were rituximab (n = 1); rituximab and temozolomide (n = 1); and bleomycin, vincristine, procarbazine, prednisone, dexamethasone, ifosfamide, carboplatin, etoposide (n = 1).
Other chemotherapies were cytarabine (n = 2); vincristine, dexamethasone, cytarabine, cisplatin (n = 1); and cyclophosphamide, thiotepa, etoposide (n = 1).
One patient had brain surgery only and was excluded from the analysis of treatment characteristics.